ANAPROX DS- naproxen sodium tablet EC-NAPROSYN- naproxen ...
Leading Innovation in Pain & Inflammation...ATB-346 Naproxen 11 • A successful Phase 2B double...
Transcript of Leading Innovation in Pain & Inflammation...ATB-346 Naproxen 11 • A successful Phase 2B double...
Leading Innovation in Pain & InflammationI N V E S T O R P R E S E N T A T I O N
JUNE 2020
Antibe Therapeutics Inc. www.antibethera.com June 2020 2
This presentation contains forward-looking information and statements which constitute “forward-looking information” under Canadian securities law and which may be material regarding, among other things, the Company’s beliefs, plans, objectives, estimates, intentions and expectations. Specific forward-looking information in this document includes, but is not limited to, statements with respect to the Company’s future operating and financial results, its research and development activities, its capital expenditure plans and the ability to execute on its future operating, investing and financing strategies. These forward-looking information and statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. We consider the assumptions on which these forward-looking statements are based to be reasonable, but caution the reader that these assumptions regarding future events, many of which are beyond our control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect us. Additional information regarding risk factors can be found in public disclosure records on SEDAR.
Our statements of “belief” in respect of our product and partner product candidates are based primarily upon our results derived to date from our research and development program. We believe that we have a reasonable scientific basis upon which we have made such statements. It is not possible, however, to predict, based upon in vitro and animal studies whether a new therapeutic agent or technology will be proved to be safe and/or effective in humans. We cannot assure that the particular results expected by us will occur.
Any forward-looking statements and statements of “belief” represent our estimates only and should not be relied upon as representing our estimates as of any subsequent date. Except as required by law, we do not assume any obligation to update any forward looking statements or statements of “belief”. We disclaim any intention or obligation to update or revise any forward- looking statements or statements of “belief”, whether as a result of new information, future events or otherwise. Nothing herein should be construed as an Offering of securities of the Company in any jurisdictions.
Forward-Looking Statements
Antibe is on the verge of solving one of the most pervasive medical problems of our time.
Antibe Therapeutics Inc. www.antibethera.com June 2020 4
Nonsteroidal anti-inflammatory drugs (“NSAIDs”) are among the most widely used medications in the world, yet they are associated with severe gastrointestinal (“GI”) ulceration and bleeding.
NSAIDs: A Massive Market Opportunity
GIA Global
Unmet Need
Damage is Pervasive
Global Market for NSAIDs1
$11 Billion
1) Global sales in 2014 (Evaluate Pharma).
Antibe Therapeutics Inc. www.antibethera.com June 2020 5
Of the sixteen drugs which hit $1 billion in sales in their first year, two were designed to address the GI-toxicity issue with NSAIDs.
NSAIDs Have a Blockbuster Pedigree
Product CompanyTherapeutic
CategoryUS Sales in First Year
Harvoni Gilead Hep C Antiviral $10.6B
Sovaldi Gilead Hep C Antiviral $9.0B
Epclusa Gilead Hep C Antiviral $3.2
Celebrex Pharmacia NSAID $2.3B
Olysio J&J Hep C Antiviral $2.1B
Tecfidera Biogen MS $1.8B
Incivek Vertex Hep C Antiviral $1.7B
Ocrevus Roche MS $1.7B
Lipitor Pfizer Statin $1.5B
Vioxx Merck & Co NSAID $1.5B
Source: Evaluate Pharma (top ten shown).
Antibe Therapeutics Inc. www.antibethera.com June 2020 6
ATB-346 was designed to deliver both GI and cardiovascular safety with non-addictive pain relief.
Addressing an Unmet Need…
Better GI Safety
Better CV Safety
ATB-346
Naproxen
Non-selective NSAIDs
The Need
Vioxx
Celebrex
Meloxicam
Several selective COX-2 NSAIDs were withdrawn or
discontinued due to increased risk of CV events1
BextraWITHDRAWN
WITHDRAWN
1. Source: FDA. Postmarket Drug Safety Information for Patients and Providers (Voluntarily Withdrawal of Vioxx, Sept/04 and FDA Request for Withdrawal of Bextra, April/05).
Schematic for illustrative purposes – not to scale
ATB-346: Lead Drug
Antibe Therapeutics Inc. www.antibethera.com June 2020 8
• Novel anti-inflammatory drug that releases hydrogen sulfide (“H2S”)
• Negligible GI damage: greatly superior to existing NSAIDs
• No significant effect on blood pressure, unlike existing NSAIDs
• Global IP and exclusivity with market protection in US to ~2031 (EU to 2033) - Patents granted in major markets (including US, Europe, Japan, China & Canada)
Our Lead Drug: ATB-346
Antibe Therapeutics Inc. www.antibethera.com June 2020 9
Hydrogen sulfide (“H2S”) has become recognized as a crucial signalling molecule with a wide range of anti-inflammatory and cytoprotective functions.
H2S: Anti-inflammatory & Cytoprotective
Nature Reviews | Drug Discovery
Analgesic
Rolling
Adhesion
r�+PJKDKVU�NGWMQE[VGs���GPFQVJGNKCN�EGNN�CFJGUKQPr�4GFWEGU�QGFGOC�HQTOCVKQP
#62�IGPGTCVKQP
ATP
2TQ�KPȯCOOCVQT[E[VQMKPGU
NF!$�
O40#
"NF!$�CEVKXCVKQP
Antioxidant
H2Se e e
ee
eeeee e e
eee
e
M1 M2
H2S
4GUQNWVKQP�QH�KPȯCOOCVKQP�
H2S
NRF2
NRF2
KEAP1
NRF2 MAF
ARE
6TCPUETKRVKQPCNN[CEVKXG�EQORNGZ
GeneVTCPUETKRVKQP
DissociationHTQO�-'#2�
H2S04(�s-'#2�RCVJYC[�
*[FTQIGP�UWNRJKFG
0GWVTQRJKN�CRQRVQUKU
4GRCKT
Vasodilation
PDE
Source: Wallace & Wang, Nature Reviews Drug Discovery 2015; 14,329-345.
Antibe Therapeutics Inc. www.antibethera.com June 2020 10
1) Source (left): Wallace & Wang, Nature Reviews Drug Discovery 2015; 14,329-345. 2) Source (right): Gemici et al., Nitric Oxide 46 (2015) 25–31.
• H2S physiological activities reduce inflammation in the gastrointestinal (“GI”) tract and prevent NSAID-induced injury
H2S Prevents NSAID-Induced Injury
Antibe Therapeutics Inc. www.antibethera.com June 2020
Gastric ulcer incidence of ATB-346 (>=3mm diameter) versus naproxen during two-week
treatment period
# of
Sub
ject
s tha
t Dev
elop
ed U
lcer
s
0
15
30
45
60
ATB-346 Naproxen
11
• A successful Phase 2B double blind GI safety study for ATB-346 was completed in March 2018 in 244 healthy volunteers
• Validation of GI safety superiority: ATB-346 exhibited an ulceration rate of 2.5% versus 42.1% for naproxen over the two-week treatment period (p<0.0001)
• ATB-346 was safe and well-tolerated
Strong Phase 2B GI Safety Data
42.1%
2.5%
(n = 118) (n = 126)
Antibe Therapeutics Inc. www.antibethera.com June 2020 12
• Strong secondary endpoint data
• Gastroduodenal ulcers and erosions - Total number of ulcers ≥3 mm: 4 for ATB-346 vs 210 for naproxen
- Large ≥5 mm ulcer incidence: 0% for ATB-346 vs 24% for naproxen
- Mean erosions per subject: 1.7 for ATB-346 vs 12.7 for naproxen
• Non-GI secondary endpoints and overall safety - Thromboxane (TXB2) inhibition for ATB-346 was not statistically
different than naproxen
- No blood pressure increases for ATB-346
- Safe and well tolerated: overall very low incidence of adverse events for ATB-346
Strong Phase 2B GI Safety Data cont’d
Total number of GI ulcers (>= 3mm diameter)
Num
ber o
f Ulc
ers
0
60
120
180
240
ATB-346 Naproxen
Incidence of large GI ulcers (>=5mm diameter)
Ulc
er In
cide
nce
0%
10%
20%
30%
40%
ATB-346 Naproxen
COX inhibition
TXB2
Syn
thes
is (p
g/m
L)
0
25
50
75
100
Day 0 Day 7 Day 14
ATB-346Naproxen
24%
0%
203
4
Antibe Therapeutics Inc. www.antibethera.com June 2020 13
• ATB-346 successfully concluded a large Phase 2B dose-ranging, efficacy study in June 2020 in patients with osteoarthritis (“OA”) of the knee
• The primary objective of the study was to evaluate the efficacy of ATB-346 in reducing OA pain versus placebo over a 14-day treatment period — it was also a dose-ranging trial to set the dose for Phase 3 development
• A total of 385 patients were randomized to placebo or one of three doses of ATB-346 administered once daily: 250 mg, 200 mg and 150 mg
• The 250 mg and 200 mg doses were powered for statistical significance and the 150 mg dose was powered to only observe an efficacy response
• Validation of efficacy: Both the 250 mg and 200 mg demonstrated unequivocal superiority to placebo, with a high level of statistical significance
• ATB-346 more potent than expected: the 150 mg dose showed a strong efficacy response — lowest effective dose still to be established
• ATB-346 was safe and well tolerated
Successful Phase 2B Dose-Ranging, Efficacy Study
Antibe Therapeutics Inc. www.antibethera.com June 2020 14
Positive Primary Endpoint Data Phase 2B Efficacy Study
PlaceboATB-346 (250 mg)
ATB-346 (200 mg)
ATB-346 (150 mg)
WOMAC pain score at baseline (day 0) 325.7 318.5 325.2 325.8
WOMAC pain score at day 4 261.4 229.8 237.4 230.2
Reduction versus baseline at day 4 (%) 20.3% 28.3% 27.3% 29.3%
WOMAC pain score at day 14 228.2 183.2 183.8 203.4
Reduction versus baseline at day 14 (%) 32.7% 43.6% 43.7% 39.3%
Primary endpoint: p-value versus placebo (day 14) - 0.01 0.007 0.13
• Pain relief observed with ATB-346 was comparable to the small open label Phase 2A efficacy study completed in 2016 (55.6% reduction versus baseline in 12 patients with 250 mg dose)
• The 250 mg and 200 mg doses of ATB-346 met the primary endpoint of pain reduction as measured by superiority to placebo, with a high level of statistical significance
WOMAC scores based on 500-point Likert scale; reduction figures normalized to 100mm WOMAC pain subscale Study population: 250 mg = 132 patients; 200 mg = 123 patients; 150 mg = 60 patients; placebo = 66 patients
Antibe Therapeutics Inc. www.antibethera.com June 2020 15
Positive Therapeutic Benefit Data Phase 2B Efficacy Study
PlaceboATB-346 (250 mg)
ATB-346 (200 mg)
ATB-346 (150 mg)
WOMAC stiffness reduction versus baseline (%) 23.8% 41.7% 40.5% 36.2%
p-value versus placebo (day 14) - < 0.001 < 0.001 0.03
WOMAC DPDA reduction versus baseline (%) 24.3% 38.4% 40.1% 32.5%
p-value versus placebo (day 14) - 0.004 0.001 0.106
• ATB-346 also demonstrated highly statistically significant reduction versus placebo in the WOMAC arthritis scores of stiffness and the difficulty of performing daily activities (“DPDA”)
Antibe Therapeutics Inc. www.antibethera.com June 2020 16
• Adverse events typically associated with NSAID use were comparable across placebo and all three treatment arms of ATB-346 and there were very few serious adverse events
Adverse Events Phase 2B Efficacy Study
Patient-reported adverse event (>= 2%) Placebo ATB-346 (150 mg) ATB-346 (200 mg) ATB-346 (250 mg)
Dyspepsia 1.5% 1.6% 4.8% 4.5%
Constipation 0.0% 4.9% 1.6% 1.5%
Diarrhea 7.6% 1.6% 1.6% 1.5%
Nausea 1.5% 1.6% 1.6% 3.0%
Dizziness 0.0% 0.0% 1.6% 3.8%
Gastroesophageal reflux disease 3.0% 3.3% 0.8% 3.0%
Abdominal pain 0.0% 0.0% 0.8% 2.3%
Abdominal pain upper 1.5% 1.6% 0.8% 2.3%
Faeces soft 3.0% 0.0% 0.0% 0.8%
Pain 3.0% 0.0% 0.8% 2.3%
Headache 3.0% 3.3% 3.2% 7.6%
Nasopharyngitis 4.5% 1.6% 0.8% 3.0%
Urinary tract infection 0.0% 3.3% 3.2% 0.0%
• During the treatment period, only 1 out of 318 patients administered ATB-346 had clinically significant, temporary liver enzyme elevations (“LTEs”) — this is a known class effect of NSAIDs
• At the post-treatment assessment, patients in the 250 mg, 200 mg and 150 mg treatment arms had LTE incidences of 12.1%, 8.0% and 8.2%, respectively — acetaminophen use, pre-existing liver conditions and concomitant statin use were associated with a majority of the LTE incidents; adjudication yields rates of 4.5%, 3.2% and 3.3%, respectively, suggesting a liver safety profile comparable to commonly prescribed NSAIDs
H2S Platform: Other Pipeline Drugs
Antibe Therapeutics Inc. www.antibethera.com June 2020 18
• Antibe has commenced IND-enabling pre-clinical studies for ATB-352, a potent and non-addictive analgesic for severe pain to address the global opioid crisis
• Post-operative pain has been identified as the lead indication, a US$9 billion market opportunity1
ATB-352: Addressing the Opioid Crisis…
Every day, over 1,000 people are treated in emergency departments for misusing prescription opioids.
“”
- US Department of Health and Human Services (2013)
0
6,000
12,000
18,000
24,000
1999 2001 2003 2005 2007 2009 2011 2013 2015
NUMBER OF DEATHS FROM OPIOID PAIN RELIEVERS*
*United States, including non-methadone synthetics (fentanyl)2
1) 2019 estimate based on US$5.9B 2010 estimate and 5.3% annual growth rate (BioPharm Insight) 2) Source: National Center on Health Statistics, CDC Wonder
Antibe Therapeutics Inc. www.antibethera.com June 2020 19
ATB-352 causes negligible GI damage in rats compared to ketoprofen, a very strong NSAID prescribed for acute pain.
ATB-352: Potent Analgesic for Acute Pain
Source: Nitric Oxide 2014 159, 1236-1246. *rat study
Antibe Therapeutics Inc. www.antibethera.com June 2020 20
• Low-dose aspirin has been known for decades to provide a dramatic reduction in the risk of stroke and, more recently, a reduction in the risk of digestive system cancers
• However, aspirin, like other NSAIDs, causes stomach ulcers and GI bleeding in an appreciable portion of the population which precludes its broad prescription by physicians
• ATB-340 is a H2S-releasing derivative of aspirin that has been shown to be GI-safe in pre-clinical studies
ATB-340: A Drug for Everyone Over 50?
Antibe Therapeutics Inc. www.antibethera.com June 2020 21
Aspirin, but not ATB-340, causes significant gastric erosions in the rat stomach.
ATB-340: Low-Dose Aspirin Derivative
Source: Gemici et al., Nitric Oxide 46 (2015) 25–31.*rat study
Citagenix: Commercial Asset in Regenerative Medicine
Antibe Therapeutics Inc. www.antibethera.com June 2020 23
• Our commercial subsidiary, Citagenix Inc. (“Citagenix”), is the market leader in Canada in dental regenerative medicine and is now growing well in the United States
Citagenix: Poised for Global Growth…
FO-162
TASO-9
BS-61
TASO-8
MPI-1
TASO-7
TASO-6
TASO-5
TASO-4
IM-15
USB-P3
SS-65
TASO-3
TASO-2
TASO-1
MA-2SM-15 SM-21 707-23D1707-2N COLLEGE
RH-4
BS-59
MA-B1 BD-158
IM-15 OBN-4
100-C15
718-107
MIR-08
MO-10
PH-79
FG-2SCZFG-1SCZ
BS-60SS-65
BD-30
100-C15MA-B1
BD-158
707-2311LS-08
BD-30
ES-13
LB-369
LB-367
LB-364
BB-46
FD-170
FG-1SCZ
FG-2SCZ
BS-60
Instrument Kits
Instruments withTungsten-CarbideInserts
Instruments withExtremely Sharp Razor Edge Atraumatic
Scissors withOne side serrated
GUIDED BONE— REGENERATION KIT —
BMTGUIDED TISSUE— REGENERATION KIT —
BMT
BD-30 Tissue Forceps MA-B1 Scalpel handle
LS-08 Ruler ES-13 Dissector
100-C15 Scalpel blades 707-2311 Double-ended explorer
FG-1SCZ Iris Super-Cut scissors, Straight BS-60 Tray for 10 instruments
FG-2SCZ Iris Super-Cut scissors, Curved FD-170 Needle holder
BB-46 Micro scalpel handle BD-158 Micro suture and membrane forceps
LB-364, 367, 369 Micro blades
SINUS LIFT— SURGERY KIT —
BMT
TASO-9 Membrane placement forceps TASO-1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Sinus lift instruments
FO-162 Bone forceps for opening the sinus IM-15 Bone Material Applicator
SS-65 Stainless steel bone well, Ø 35 mm MPI-1 Membrane Placement Instrument
BS-61 Tray for 20 instruments USB-P3 Bone grafting packer
COLLEGE Dressing forceps 707-2N Double-ended periodontal probe
SM-15 Periodontal probe 707-23D1 Double-ended explorer / probe
SM-21 Periodontal probe BS-59 Tray for 5 instruments
MA-2 Mirror handle
PERIODONTAL— EXAM KIT —
BMT
SHARP
SHARP
SHARP
TUNGSTENCARBIDE
SERRATED
TUNGSTENCARBIDE
SERRATED
PH-79 Needle Holder, 145 mm MO-10 Surgical Curette
FG-1SCZ Iris Super-Cut scissors, Straight MIR-08 Periosteal Raspatory
FG-2SCZ Iris Super-Cut scissors, Curved 718-107 Periodontal Chisel
100-C15 Scalpel Blades OBN-4 Gingivectomy Knives
SS-65 Stainless steel bone well, Ø 35 mm BD-158 Micro Suture and Membrane Forceps
MA-B1 #5 Scalpel Handle BD-30 Tissue Forceps IM-15 Applicator for Bone Material BS-60 Tray for 10 instruments
BLUNT
SHARP
SHARP
SHARP
BLUNT
SHARP
SHARP
SHARP
17
Bone Graft Substitutes
Dental Barrier Membranes
High Quality Instruments
Global Market for Oral Tissue Regeneration2
US$700 MILLION
Citagenix has a $10M1 revenue base and has initiated a global growth strategy
Regenerative medicine is growing globally at 30%+3
DBM RPM
ABM
Bone Graft Substitutes
Demineralized bone matrix with cancellous boneDynaBlast™ is a composite graft product that combines osteoinductive and osteoconductive elements in a proprietary, reverse phase medium for superior handling.
Demineralized bone matrixDynaGraft·D™ is a !rst generation demineralized bone matrix in a reverse phase medium for superior handling.
DynaGraft·D™ 0.5 cc syringe - (gel) 10-110-10501 cc syringe - (gel) 10-110-10601 cc jar - (putty) 10-120-10502.5 cc jar - (putty) 10-120-1060
Applications
DynaGraft·D• Periodontal defects• Extraction site repair• Implant site development• Sinus lift procedures• Coronal defects around immediate implants
DBM RPM
DynaBlast™ 0.5 cc syringe - (paste) 10-210-10501 cc syringe - (paste) 10-210-10603 cc syringe - (paste) 10-210-10701 cc jar - (putty) 10-220-10302.5 cc jar - (putty) 10-220-1040
Applications
DynaBlast• Extraction site repair• Implant dehiscence defects• Sinus lift procedures• Moderate localized ridge defects
DBM RPM
CANCELLOUS
Demineralized bone matrix puttyAccell Connexus is a high surface area demineralized bone matrix (ABM) that incorporates a highly biocompatible Reverse Phase Medium (RPM) for robust handling.
Accell Connexus® 0.5 cc syringe - (putty) 10-310-10501 cc syringe - (putty) 10-310-1060
Applications Accell Connexus
• When the highest level of growth factors is desired• Osseous defects• In combination with less osteoinductive materials• Implant site preparation or repair
Features & Bene!ts• Highest osteoinductive potential • RPM thickens at body temperature• Resists irrigation• Ready to use
Synthetic resorbable bone substituteSynthetic resorbable bone substitute that uses the mineral building blocks naturally found in human bone. Eclipse™ goes a step beyond with its unique combination of micro and macroporosity technology.
Granules: 80% ß-tcp - 20% HA — Putty: 40% ß-tcp - 60% HA
Applications• Ridge preservation• Extraction site repair• Sinus lifts• Ridge augmentation• Osseous defects• Periodontal defects
Eclipse™May be used alone or mixed with DBM
Putty for osteoinductive potential.
Eclipse™ Granules 0.5 to 1.0 mm0.25 cc (vial) E1G0020.5 cc (vial) E1G0051 cc (vial) E1G0100.5 cc (syringe) E1GS0051.0 cc (2 x 0.5 cc syringes in a single sterile package) E1GS010
Eclipse™ Granules 1.0 to 2.0 mm 2.0 cc (vial) E2G020
Eclipse™ Putty 40 | 60 0.5 cc (syringe) E1P0051.0 cc (2 x 0.5cc syringes in separate sterile packages) E1P010
71) Annual run rate based on the nine month period ended December 31, 2019 2) Source: Straumann 2016 Annual Report (page 53) assuming USD:CHF FX rate of 1.00 : 1.00 3) Source: BCC Research LLC, September 2016
Corporate Information
Antibe Therapeutics Inc. www.antibethera.com June 2020 25
• Dan Legault JD CHIEF EXECUTIVE OFFICER
• John Wallace PhD, MBA CHIEF SCIENTIFIC OFFICER
• Joseph Stauffer DO, MBA CHIEF MEDICAL OFFICER
• David Vaughan PhD CHIEF DEVELOPMENT OFFICER
• Alain Wilson MBA CHIEF FINANCIAL OFFICER
• Scott Curtis MEng, CFA EXECUTIVE VP
• Rami Batal PhD, MBA SENIOR VP, COMMERCIAL STRATEGY
Management & Board of Directors
Management Board of Directors• Walt Macnee MBA Chairman
VICE CHAIRMAN / MASTERCARD INC.
• Roderick Flower PhD EMERITUS PROFESSOR OF PHARMACOLOGY / WILLIAM HARVEY RESEARCH INSTITUTE (WHRI)
• Amal Khouri MBA VP, BUSINESS DEVELOPMENT / KNIGHT THERAPEUTICS INC.
• Dan Legault JD CHIEF EXECUTIVE OFFICER
• John Wallace PhD, MBA CHIEF SCIENTIFIC OFFICER
• Yung Wu CHIEF EXECUTIVE OFFICER / MARS DISCOVERY DISTRICT
Antibe Therapeutics Inc. www.antibethera.com June 2020 26
Our clinical and scientific advisory boards are comprised of world-class scientists, including a Nobel Laureate.
World-Class Scientific Advisors
• Dr. Andre Buret PhD CALGARY, ALBERTA
• Dr. Francis Chan MD, PhD HONG KONG, CHINA
• Dr. Giuseppe Cirino PhD NAPLES, ITALY
• Dr. Peter B. Ernst DVM, PhD SAN DIEGO, CALIFORNIA
• Dr. Derek Gilroy PhD LONDON, ENGLAND
• Dr. Richard H. Hunt MD OXFORD, ENGLAND
• Dr. Louis J. Ignarro PhD LOS ANGELES, CALIFORNIA
• Dr. Angel Lanas MD, DSc ZARAGOZA, SPAIN
• Dr. Gilberto de Nucci MD, PhD SAO PAOLO, BRAZIL
• Dr. Daniel K. Podolsky MD DALLAS, TEXAS
• Dr. James Scheiman BS, MD CHARLOTTESVILLE, VIRGINIA
• Dr. William Sessa PhD NEW HAVEN, CONNECTICUT
• Dr. Philip M. Sherman MD TORONTO, ONTARIO
• Dr. J. Carter Thorne MD, FRCP(C), FACP NEWMARKET, ONTARIO
Antibe Therapeutics Inc. www.antibethera.com June 2020 27
• Angus Russell CA
- Former CEO of Shire (2008 - 2013) — led expansion into new therapeutic areas through a series of late-stage deals
- Currently Chairman of Mallinckrodt, a leading global specialty pharma company
• Dominique Monnet MBA
- Responsible for accelerating growth of Amgen’s Inflammation division and its Enbrel® franchise
- Currently President of PDL BioPharma, a manager of healthcare companies, products and royalties
• Andrew Powell JD
- Played instrumental role in the sale of: Medivation to Pfizer for US$14B; InterMune to Roche for US$8.3B; ImClone to Eli Lilly for US$6.5B
- Currently a director at Aclaris Therapeutics, a biopharma company focused on dermatology
Partnering Advisory Team
Antibe Therapeutics Inc. www.antibethera.com June 2020 28
Capitalization Summary
Stock Symbols TSXV-ATE; OTCQB-ATBPF
Share Price(1) $0.60
Shares Outstanding 309M
Stock Options & RSUs 38M
Warrants 17M
Market Capitalization(1) $186M
Cash & Equivalents(2) $6M
Insider Ownership FULLY DILUTED 19%
Annual Sales(3) $10M
1) As of market close June 3, 2020 2) As of May 1, 2020 (disclosed in May 4, 2020 press release) 3) Annual run rate based on the nine month period ended December 31, 2019
Volu
me
(mill
ions
)
1
2
3
4
5
Shar
e Pr
ice
(CAD
)
$0.10
$0.20
$0.30
$0.40
$0.50
$0.60
$0.70
$0.80
Jun-19 Jul-19 Aug-19 Oct-19 Nov-19 Jan-20 Feb-20 Apr-20 May-20
Antibe Therapeutics Inc. www.antibethera.com June 2020 29
• Best-in-class drug platform: Antibe’s proprietary hydrogen sulfide (“H2S”) technology represents a major medical advance in the safe treatment of pain & inflammation
• Strong Phase 2B GI safety data: Antibe’s lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate)
• Human proof-of-concept fully validated, moving onto Phase 3: ATB-346 demonstrated superiority to placebo in pain relief in a large Phase 2B dose-ranging, efficacy study
• Potential to disrupt global pain market: the global pain market, including opioids, exceeds $20 billion and would benefit greatly from GI-safe and non-addictive therapies
• Commercial asset in regenerative medicine: Antibe’s subsidiary, Citagenix, is poised for growth in the dental biologics market with a revenue base of $10 million1
• Seasoned management team, Board of Directors and advisors
Key Takeaways
1) Annual run rate based on the nine month period ended December 31, 2019
Thank You.
ANTIBE THERAPEUTICS INC.
15 Prince Arthur Avenue, Toronto, ON M5R 1B2
+1 416 – 473 – 4095
antibethera.com
TSXV: ATE
OTCQB: ATBPF